Celldex Therapeutics (CLDX) : During the past 4 weeks, traders have been relatively bearish on Celldex Therapeutics (CLDX), hence the stock is down -16.99% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -11.41% relative to the S&P 500. The 4-week change in the price of the stock is -16.67% and the stock has fallen -11.44% in the past 1 week.
Celldex Therapeutics, Inc. has dropped 1.99% during the last 3-month period . Year-to-Date the stock performance stands at -74.81%. The stock has recorded a 20-day Moving Average of 13.29% and the 50-Day Moving Average is 12.06%.
Celldex Therapeutics (NASDAQ:CLDX): The stock opened at $4.15 on Friday but the bulls could not build on the opening and the stock topped out at $4.15 for the day. The stock traded down to $3.84 during the day, due to lack of any buying support eventually closed down at $3.95 with a loss of -5.05% for the day. The stock had closed at $4.16 on the previous day. The total traded volume was 9,054,269 shares.
Also, Equity analysts at the Brokerage firm Jefferies maintains its rating on Celldex Therapeutics (NASDAQ:CLDX). The rating major has initiated the coverage with hold rating on the shares. The Analysts at Jefferies raises the price target from $4 per share to $5 per share. The rating by the firm was issued on August 9, 2016.
Celldex Therapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other difficult-to-treat diseases. The Company is engaged in the development of targeted immunotherapeutics comprised of antibodies, adjuvants and monotherapies and antibody-drug conjugates that treat cancers and other diseases. Its lead drug candidates include rindopepimut also referred to as Rintega and CDX-110 and glembatumumab vedotin also referred to as CDX-011. Its early-stage drug candidates in clinical development, includes varlilumab also referred to as CDX-1127, a fully human therapeutic monoclonal antibody for cancer indications, CDX-1401, a targeted immunotherapeutic for cancer indications and CDX-301, an immune cell mobilizing agent and dendritic cell growth factor. CDX-014 is a preclinical product under development for the treatment of cancer.